Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP

Cory M. Nadel, Saugat Pokhrel, Kristin Wucherer, Abby Oehler, Aye C. Thwin, Koli Basu, Matthew D. Callahan, Daniel R. Southworth, Daniel A. Mordes, Charles S. Craik and Jason E. Gestwicki ()
Additional contact information
Cory M. Nadel: University of California San Francisco
Saugat Pokhrel: University of California San Francisco
Kristin Wucherer: University of California San Francisco
Abby Oehler: University of California San Francisco
Aye C. Thwin: University of California San Francisco
Koli Basu: University of California San Francisco
Matthew D. Callahan: University of California San Francisco
Daniel R. Southworth: University of California San Francisco
Daniel A. Mordes: University of California San Francisco
Charles S. Craik: University of California San Francisco
Jason E. Gestwicki: University of California San Francisco

Nature Communications, 2024, vol. 15, issue 1, 1-15

Abstract: Abstract Microtubule-associated protein tau (MAPT/tau) accumulates in a family of neurodegenerative diseases, including Alzheimer’s disease (AD). In disease, tau is aberrantly modified by post-translational modifications (PTMs), including hyper-phosphorylation. However, it is often unclear which of these PTMs contribute to tau’s accumulation or what mechanisms might be involved. To explore these questions, we focus on a cleaved proteoform of tau (tauC3), which selectively accumulates in AD and was recently shown to be degraded by its direct binding to the E3 ubiquitin ligase, CHIP. Here, we find that phosphorylation of tauC3 at a single residue, pS416, is sufficient to weaken its interaction with CHIP. A co-crystal structure of CHIP bound to the C-terminus of tauC3 reveals the mechanism of this clash, allowing design of a mutation (CHIPD134A) that partially restores binding and turnover of pS416 tauC3. We confirm that, in our models, pS416 is produced by the known AD-associated kinase, MARK2/Par-1b, providing a potential link to disease. In further support of this idea, an antibody against pS416 co-localizes with tauC3 in degenerative neurons within the hippocampus of AD patients. Together, these studies suggest a molecular mechanism for how phosphorylation at a discrete site contributes to accumulation of a tau proteoform.

Date: 2024
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-024-52075-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:15:y:2024:i:1:d:10.1038_s41467-024-52075-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-024-52075-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().